Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Przeglądasz jako GOŚĆ
Zmień bibliotekę

Wyszukujesz frazę ""7512719"" wg kryterium: JN


Tytuł :
Re: Matthew Mossanena, Filipe L.F. Carvalhoa, Vinayak Muralidhar, et al. Genomic Features of Muscle-invasive Bladder Cancer Arising After Prostate Radiotherapy. Eur Urol 2022;81:466-73.
Autorzy :
Song Y; Department of Urology, Peking University People's Hospital, Beijing, China.
Du Y; Department of Urology, Peking University People's Hospital, Beijing, China.
Xu T; Department of Urology, Peking University People's Hospital, Beijing, China. Electronic address: .
Pokaż więcej
Źródło :
European urology [Eur Urol] 2022 Aug 05. Date of Electronic Publication: 2022 Aug 05.
Typ publikacji :
Letter
Opinia redakcyjna
Tytuł :
We Must Change Our Approach to Racial Disparities in Prostate Cancer.
Autorzy :
Washington SL; Department of Urology, Helen Diller Family Comprehensive Cancer Center, University of California-San Francisco, San Francisco, CA, USA; Department of Epidemiology & Biostatistics, University of California-San Francisco, San Francisco, CA, USA; Department of Medicine, University of California-San Francisco, San Francisco, CA, USA. Electronic address: .
Pokaż więcej
Źródło :
European urology [Eur Urol] 2022 Aug 04. Date of Electronic Publication: 2022 Aug 04.
Typ publikacji :
Editorial
Opinia redakcyjna
Tytuł :
Local Failure Events in Prostate Cancer Treated with Radiotherapy: A Pooled Analysis of 18 Randomized Trials from the Meta-analysis of Randomized Trials in Cancer of the Prostate Consortium (LEVIATHAN).
Autorzy :
Ma TM; Depart of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Chu FI; Depart of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Sandler H; Department of Radiation Oncology, Cedars Sinai, Los Angeles, CA, USA.
Feng FY; Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Efstathiou JA; Department of Radiation Oncology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Jones CU; Department of Radiation Oncology, Sutter Medical Group, Roseville, CA, USA.
Roach M 3rd; Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
Rosenthal SA; Department of Radiation Oncology, Sutter Medical Group, Roseville, CA, USA.
Pisansky T; Department of Radiation Oncology, Mayo Clinic, Rochester, MN, USA.
Michalski JM; Department of Radiation Oncology, Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
Bolla M; Department of Radiation Therapy, CHU Grenoble, Grenoble, France.
de Reijke TM; Department of Urology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands.
Maingon P; Department of Radiation Oncology, Centre Georges François Leclerc, University of Burgundy, Dijon, Burgundy, France.
Neven A; Luxembourg Institute of Health, Competence Center for Methodology and Statistics, Strassen, Luxembourg.
Denham J; School of Medicine and Public Health, Faculty of Health and Medicine University of Newcastle, Newcastle, NSW, Australia.
Steigler A; School of Medicine and Public Health, Faculty of Health and Medicine University of Newcastle, Newcastle, NSW, Australia.
Joseph D; Department of Surgery, University of Western Australia.
Nabid A; Department of Radiation Oncology, Centre Hospitaler Universitaire de Sherbrooke, Sherbrooke, QC, Canada.
Souhami L; Department of Radiation Oncology, McGill University Health Centre, Montreal, QC, Canada.
Carrier N; Centre de recherche clinique, Centre Hospitalier Universitaire de Sherbrooke, Sherbrooke, QC, Canada.
Incrocci L; Department of Radiation Oncology, Erasmus Medical Center, Rotterdam, The Netherlands.
Heemsbergen W; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Pos FJ; Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Sydes MR; MRC Clinical Trials Unit at UCL, University College London, London, UK.
Dearnaley DP; Academic Urology Unit, Royal Marsden Hospital, London, UK; The Institute of Cancer Research, London, UK.
Tree AC; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.
Syndikus I; Clatterbridge Cancer Centre, Wirral, UK.
Hall E; The Institute of Cancer Research, London, UK.
Cruickshank C; The Institute of Cancer Research, London, UK.
Malone S; The Ottawa Hospital Cancer Centre, Ottawa Hospital Research Institute, Ottawa, Ontario, Canada.
Roy S; Department of Radiation Oncology, Rush University Medical Center, Chicago, IL, USA.
Sun Y; Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, OH, USA; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Zaorsky NG; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Nickols NG; Depart of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Reiter RE; Department of Urology, University of California Los Angeles, Los Angeles, CA, USA.
Rettig MB; Department of Urology, University of California Los Angeles, Los Angeles, CA, USA; Division of Hematology/Oncology, Department of Medicine, University of California Los Angeles, Los Angeles, CA, USA.
Steinberg ML; Depart of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Reddy VK; Depart of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Xiang M; Depart of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA.
Romero T; Department of Medicine Statistics Core, University of California Los Angeles, Los Angeles, CA, USA.
Spratt DE; Department of Radiation Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
Kishan AU; Depart of Radiation Oncology, University of California Los Angeles, Los Angeles, CA, USA. Electronic address: .
Pokaż więcej
Corporate Authors :
Meta-analysis of Randomized trials in Cancer of the Prostate MARCAP Consortium investigators
Źródło :
European urology [Eur Urol] 2022 Aug 04. Date of Electronic Publication: 2022 Aug 04.
Typ publikacji :
Journal Article; Review
Czasopismo naukowe
Tytuł :
Phase 1 Study of Chemoradiotherapy Combined with Nivolumab ± Ipilimumab for the Curative Treatment of Muscle-invasive Bladder Cancer.
Autorzy :
de Ruiter BM; Department of Urology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands; Cancer Center Amsterdam, Amsterdam, The Netherlands.
van Hattum JW; Department of Urology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands; Cancer Center Amsterdam, Amsterdam, The Netherlands.
Lipman D; Department of Radiation Oncology, Isala Hospital Zwolle, Zwolle, The Netherlands.
de Reijke TM; Department of Urology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands; Cancer Center Amsterdam, Amsterdam, The Netherlands.
van Moorselaar RJA; Cancer Center Amsterdam, Amsterdam, The Netherlands; Department of Radiotherapy, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
van Gennep EJ; Department of Urology, Leiden University Medical Center, Leiden University, Leiden, The Netherlands.
Maartje Piet AH; Cancer Center Amsterdam, Amsterdam, The Netherlands; Department of Radiotherapy, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Donker M; Department of Radiotherapy, Leiden University Medical Center, Leiden University, Leiden, The Netherlands.
van der Hulle T; Department of Medical Oncology, Leiden University Medical Center, Leiden University, Leiden, The Netherlands.
Voortman J; Cancer Center Amsterdam, Amsterdam, The Netherlands; Department of Medical Oncology, Amsterdam UMC location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
Oddens JR; Department of Urology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands; Cancer Center Amsterdam, Amsterdam, The Netherlands.
Hulshof MCCM; Cancer Center Amsterdam, Amsterdam, The Netherlands; Department of Radiotherapy, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands.
Bins AD; Cancer Center Amsterdam, Amsterdam, The Netherlands; Department of Medical Oncology, Amsterdam UMC location University of Amsterdam, Amsterdam, The Netherlands. Electronic address: .
Pokaż więcej
Źródło :
European urology [Eur Urol] 2022 Aug 03. Date of Electronic Publication: 2022 Aug 03.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Re: Effect of Robot-assisted Radical Cystectomy with Intracorporeal Urinary Diversion vs Open Radical Cystectomy on 90-Day Morbidity and Mortality Among Patients with Bladder Cancer: A Randomized Clinical Trial.
Autorzy :
Skolarikos A; School of Medicine, National and Kapodistrian University of Athens, Athens, Greece; Second Department of Urology, Sismanogleio Hospital, Athens, Greece. Electronic address: .
Pokaż więcej
Źródło :
European urology [Eur Urol] 2022 Aug 03. Date of Electronic Publication: 2022 Aug 03.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Re: Fragmentation of Stones by Burst Wave Lithotripsy in the First 19 Humans.
Autorzy :
Yang H; Department of Urology, University of California-San Francisco, San Francisco, CA, USA. Electronic address: .
Stoller M; Department of Urology, University of California-San Francisco, San Francisco, CA, USA.
Pokaż więcej
Źródło :
European urology [Eur Urol] 2022 Aug 03. Date of Electronic Publication: 2022 Aug 03.
Typ publikacji :
Journal Article
Czasopismo naukowe
Tytuł :
Lingual Mucosal Graft Ureteroplasty for Long Proximal Ureteral Stricture: 6 Years of Experience with 41 Cases.
Autorzy :
Liang C; Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Department of Urology, The First Affiliated Hospital of Shenzhen University, Shenzhen, China.
Wang J; Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hai B; Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xu Y; Department of Urology, The First Affiliated Hospital of Wannan Medical College, Wuhu, China.
Zeng J; Department of Urology, Jingzhou Central Hospital, Yangtze University, Jingzhou, China.
Chai S; Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Chen J; Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Zhang H; Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Gao X; Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Cheng G; Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Yang X; Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Hou T; Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Li W; Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Xiao X; Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: .
Li B; Department of Urology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China; Institute of Urology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. Electronic address: .
Pokaż więcej
Źródło :
European urology [Eur Urol] 2022 Aug; Vol. 82 (2), pp. 193-200. Date of Electronic Publication: 2022 May 23.
Typ publikacji :
Journal Article
MeSH Terms :
Ureter*/surgery
Ureteral Obstruction*/surgery
Constriction, Pathologic/surgery ; Humans ; Mouth Mucosa/transplantation ; Retrospective Studies ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Rare Germline Variants Are Associated with Rapid Biochemical Recurrence After Radical Prostate Cancer Treatment: A Pan Prostate Cancer Group Study.
Autorzy :
Burns D; The Institute of Cancer Research, London, UK.
Anokian E; The Institute of Cancer Research, London, UK.
Saunders EJ; The Institute of Cancer Research, London, UK.
Bristow RG; Manchester Cancer Research Centre and CRUK Manchester Institute, The University of Manchester, Manchester, UK.
Fraser M; Princess Margaret Cancer Centre/University Health Network, Toronto, Ontario, Canada; Computational Biology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada.
Reimand J; Computational Biology Program, Ontario Institute for Cancer Research, Toronto, Ontario, Canada; Department of Medical Biophysics & Department of Molecular Genetics, University of Toronto, Toronto, Ontario, Canada.
Schlomm T; Charité - Universitätsmedizin Berlin, Berlin, Germany.
Sauter G; University Medical Centre Hamburg - Eppendorf, Hamburg, Germany.
Brors B; German Cancer Research Center (DKFZ), Deutsches Krebsforschungszentrum, Heidelberg, Germany.
Korbel J; European Molecular Biology Laboratory (EMBL), Heidelberg, Germany.
Weischenfeldt J; Charité - Universitätsmedizin Berlin, Berlin, Germany; Biotech Research & Innovation Centre (BRIC) & Finsen Laboratory, University of Copenhagen, Rigshospitalet, Copenhagen, Denmark.
Waszak SM; Centre for Molecular Medicine Norway (NCMM), Nordic EMBL Partnership, University of Oslo and Oslo University Hospital, Oslo, Norway; Department of Neurology, University of California, San Francisco, San Francisco, CA, USA; Department of Pediatric Research, Division of Pediatric and Adolescent Medicine, Rikshospitalet, Oslo University Hospital, Oslo, Norway.
Corcoran NM; Department of Surgery, The University of Melbourne, Grattan Street, Parkville, Victoria, Australia; Department of Urology, Royal Melbourne Hospital, Parkville, Victoria, Australia; Melbourne Bioinformatics, The University of Melbourne, Grattan Street, Victoria, Australia.
Jung CH; The University of Melbourne, Grattan Street, Parkville, Victoria, Australia.
Pope BJ; Department of Surgery, The University of Melbourne, Grattan Street, Parkville, Victoria, Australia; Royal Melbourne Hospital, Melbourne, Parwille, Victoria, Australia.
Hovens CM; Melbourne Bioinformatics, The University of Melbourne, Grattan Street, Victoria, Australia; The University of Melbourne, Grattan Street, Parkville, Victoria, Australia; University of Melbourne Centre for Cancer Research, The Victorian Comprehensive Cancer Centre, Parkville, Victoria, Australia.
Cancel-Tassin G; CeRePP, Hopital Tenon, Paris, France; Sorbonne Universite, GRC n°5 Predictive Onco-Urology, APHP, Tenon Hospital, Paris, France.
Cussenot O; CeRePP, Hopital Tenon, Paris, France; Sorbonne Universite, GRC n°5 Predictive Onco-Urology, APHP, Tenon Hospital, Paris, France.
Loda M; Department of Pathology & Laboratory Medicine, Weill Cornell Medicine, New York, NY, USA.
Sander C; cBio Center, Dana-Farber Cancer Institute, Boston, MA, USA.
Hayes VM; Garvan Institute of Medical Research, The Kinghorn Cancer Centre, Darlinghurst, NSW, Australia; School of Medical Sciences, University of Sydney, Charles Perkins Centre, Camperdown, NSW, Australia.
Dalsgaard Sorensen K; Department of Molecular Medicine, Aarhus University Hospital, Aarhus N, Denmark; Department of Clinical Medicine, Aarhus University Hospital, Aarhus N, Denmark.
Lu YJ; Centre for Biomarker and Therapeutics, Barts Cancer Institute, Queen Mary University of London, London, UK.
Hamdy FC; Nuffield Department of Surgical Sciences University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK.
Foster CS; The Institute of Cancer Research, London, UK.
Gnanapragasam V; Department of Surgery, Division of Urology, University of Cambridge, Cambridge, UK.
Butler A; Wellcome Trust Sanger Institute, Genome Campus, Hinxton, Cambridge, UK.
Lynch AG; School of Medicine, University of St Andrews, St Andrews, Fife, UK; School of Mathematics & Statistics, St Andrews, Fife, UK.
Massie CE; CRUK Cambridge Institute, Hutchison MRC Research Centre, University of Cambridge, Li Ka Shing Centre, Cambridge, UK.
Woodcock DJ; Nuffield Department of Surgical Sciences, University of Oxford, John Radcliffe Hospital, Headington, Oxford, UK.
Cooper CS; Norwich Medical School, University of East Anglia, Norwich, UK.
Wedge DC; Manchester Cancer Research Centre, The University of Manchester, Manchester, UK.
Brewer DS; Norwich Medical School, University of East Anglia, Norwich, UK; The Earlham Institute, Norwich Research Park, Norwich, UK.
Kote-Jarai Z; The Institute of Cancer Research, London, UK. Electronic address: .
Eeles RA; The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, London, UK.
Pokaż więcej
Corporate Authors :
CR-UK/Prostate Cancer UK, ICGC, The PPCG; CR-UK/Prostate Cancer UK, ICGC, The Pan Prostate Cancer Group, UK.
Źródło :
European urology [Eur Urol] 2022 Aug; Vol. 82 (2), pp. 201-211. Date of Electronic Publication: 2022 May 31.
Typ publikacji :
Journal Article
MeSH Terms :
Phosphatidylinositol 3-Kinases*/genetics
Prostatic Neoplasms*/surgery
Prostatic Neoplasms*/therapy
Germ Cells ; Germ-Line Mutation ; Humans ; Male ; Neoplasm Recurrence, Local/genetics ; Prostatectomy ; Proto-Oncogene Proteins c-akt/genetics ; Proto-Oncogene Proteins p21(ras)/genetics ; TOR Serine-Threonine Kinases
Czasopismo naukowe
Tytuł :
Re: Øyvind Ulvik, Mathias Sørstrand Æsøy, Patrick Juliebø-Jones, Peder Gjengstø, Christian Beisland. Thulium Fibre Laser versus Holmium:YAG for Ureteroscopic Lithotripsy: Outcomes from a Prospective Randomised Clinical Trial. Eur Urol. 2022;82:73-9.
Autorzy :
Yaghoubian AJ; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA. Electronic address: .
Khusid JA; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Gupta M; Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
Pokaż więcej
Źródło :
European urology [Eur Urol] 2022 Aug; Vol. 82 (2), pp. e43-e44. Date of Electronic Publication: 2022 Jun 02.
Typ publikacji :
Letter; Randomized Controlled Trial
MeSH Terms :
Lasers, Solid-State*/therapeutic use
Lithotripsy*
Lithotripsy, Laser*
Holmium ; Humans ; Lasers ; Prospective Studies ; Thulium ; Ureteroscopy
Raport
Tytuł :
The SEMITEP Trial: Less May Be More.
Autorzy :
Albers P; Department of Urology, Düsseldorf University Hospital, Heinrich-Heine University Medical Faculty, Düsseldorf, Germany. Electronic address: .
Pokaż więcej
Źródło :
European urology [Eur Urol] 2022 Aug; Vol. 82 (2), pp. 180-181. Date of Electronic Publication: 2022 May 20.
Typ publikacji :
Editorial
Opinia redakcyjna
Tytuł :
Re: Jiatong Zhou, Jie Ding, Jun Qi. Comparison of Typical Prostate Adenocarcinoma and Rare Histological Variant Prostate Cancer Showed Different Characteristics and Prognosis: A Surveillance, Epidemiology, and End Results Database Analysis. Eur Urol. 2022;82:152-5.
Autorzy :
Song Y; Department of Urology, Peking University People's Hospital, Beijing, China.
Du Y; Department of Urology, Peking University People's Hospital, Beijing, China. Electronic address: .
Xu T; Department of Urology, Peking University People's Hospital, Beijing, China. Electronic address: .
Pokaż więcej
Źródło :
European urology [Eur Urol] 2022 Aug; Vol. 82 (2), pp. e47-e48. Date of Electronic Publication: 2022 May 20.
Typ publikacji :
Letter
Opinia redakcyjna
Tytuł :
The GETUG SEMITEP Trial: De-escalating Chemotherapy in Good-prognosis Seminoma Based on Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography.
Autorzy :
Loriot Y; Gustave Roussy, Département de médecine oncologique, INSERM U981, Université Paris-Saclay, Villejuif, France. Electronic address: .
Texier M; Gustave Roussy, INSERM U1018, Université Paris Saclay, Villejuif, France.
Culine S; Department of Medical Oncology, Saint-Louis-APHP, Faculté de Paris, Paris, France.
Fléchon A; Department of Medical Oncology, Léon Bérard Cancer Center, Lyon, France.
Thiery-Vuillemin A; Service d'Oncologie médicale, CHU Besançon, Besançon, France.
Gravis G; Department of Medical Oncology, Paoli-Calmette Institute, Marseille, France.
Geoffrois L; Medical Oncology, Institute of Cancerology of Lorraine - Alexis Vautrin, Vandoeuvre Les Nancy, France.
Chevreau C; Department of Medical Oncology, Institut Claudius Regaud IUCT-O, Toulouse, France.
Gross-Goupil M; Department of Medical Oncology, Bordeaux University Hospital, Bordeaux, France.
Barthelemy P; Institut de Cancérologie Strasbourg Europe (ICANS), Strasbourg, France.
Bompas E; Medical Oncology Department, ICO, Saint Herblain, Pays de la Loire, France.
Mahammedi H; Centre Jean Perrin, Clermont-Ferrand, France.
Laguerre B; Department of Medical Oncology, Eugene Marquis Cancer Center, Rennes, France.
Lacourtoisie SA; Western Cancer Institute, Paul Papin Site, Angers, France.
Helissey C; Clinical Research Unit, Military Hospital Begin, Saint Mandé, France.
Ladoire S; Department of Medical Oncology, Centre Georges-François Leclerc, Dijon, France.
Abraham C; Department of Medical Oncology, Centre Hospitalier Versailles André Mignot, Le Chesnay, France.
Massard C; Gustave Roussy, DITEP, Université Paris-Saclay, Villejuif, France.
Grimaldi S; Gustave Roussy, Department of Nuclear Medicine and Endocrine Oncology, Université Paris-Saclay, Villejuif, France.
Fizazi K; Gustave Roussy, Département de médecine oncologique, INSERM U981, Université Paris-Saclay, Villejuif, France.
Pokaż więcej
Źródło :
European urology [Eur Urol] 2022 Aug; Vol. 82 (2), pp. 172-179. Date of Electronic Publication: 2022 May 20.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Seminoma*/diagnostic imaging
Seminoma*/drug therapy
Seminoma*/secondary
Testicular Neoplasms*/diagnostic imaging
Testicular Neoplasms*/drug therapy
Testicular Neoplasms*/pathology
Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carboplatin/adverse effects ; Fluorodeoxyglucose F18 ; Humans ; Male ; Positron Emission Tomography Computed Tomography/methods ; Positron-Emission Tomography ; Prognosis ; Radiopharmaceuticals/therapeutic use ; Treatment Outcome
Czasopismo naukowe
Tytuł :
Re: Bladder Cancer in Patients Younger than 40 Years: Outcomes from the National Cancer Database de la Calle CM, Washington SL 3rd, Lonergan PE, et al World J Urol 2021;39:1911-6.
Autorzy :
Radziszewski P; Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland.
Szabłoński W; Department of General, Oncological and Functional Urology, Medical University of Warsaw, Warsaw, Poland. Electronic address: .
Pokaż więcej
Źródło :
European urology [Eur Urol] 2022 Aug; Vol. 82 (2), pp. 243-244. Date of Electronic Publication: 2022 May 20.
Typ publikacji :
Journal Article
MeSH Terms :
Urinary Bladder Neoplasms*
Humans ; Rare Diseases ; Washington
Czasopismo naukowe
Tytuł :
Re: Øyvind Ulvik, Mathias Sørstrand Æsøy, Patrick Juliebø-Jones, Peder Gjengstø, Christian Beisland. Thulium Fibre Laser versus Holmium:YAG for Ureteroscopic Lithotripsy: Outcomes from a Prospective Randomised Clinical Trial. Eur Urol. 2022;82:73-9.
Autorzy :
Kim HJ; Division of Endourology, Department of Urology, University of Michigan, Ann Arbor, MI, USA. Electronic address: .
Ghani KR; Division of Endourology, Department of Urology, University of Michigan, Ann Arbor, MI, USA.
Pokaż więcej
Źródło :
European urology [Eur Urol] 2022 Aug; Vol. 82 (2), pp. e39-e40. Date of Electronic Publication: 2022 May 21.
Typ publikacji :
Letter; Randomized Controlled Trial
MeSH Terms :
Lasers, Solid-State*/therapeutic use
Lithotripsy*
Lithotripsy, Laser*
Holmium ; Humans ; Lasers ; Prospective Studies ; Thulium ; Ureteroscopy
Raport
Tytuł :
Re: Yaw A. Nyame, Matthew R. Cooperberg, Marcus G. Cumberbatch, et al. Deconstructing, Addressing, and Eliminating Racial and Ethnic Inequities in Prostate Cancer Care. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.03.007.
Autorzy :
Wei Y; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Ye D; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.
Zhu Y; Department of Urology, Fudan University Shanghai Cancer Center, Shanghai, China; Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China. Electronic address: .
Pokaż więcej
Źródło :
European urology [Eur Urol] 2022 Aug; Vol. 82 (2), pp. e51. Date of Electronic Publication: 2022 May 20.
Typ publikacji :
Letter
MeSH Terms :
Abiraterone Acetate*
Prostatic Neoplasms*/therapy
Humans ; Male ; Prostate
Opinia redakcyjna
Tytuł :
Final Results of Neoadjuvant Atezolizumab in Cisplatin-ineligible Patients with Muscle-invasive Urothelial Cancer of the Bladder.
Autorzy :
Szabados B; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK; Department of Urology, University College London Hospitals NHS Foundation Trust, London, UK.
Kockx M; CellCarta N V, Wilrijk, Belgium.
Assaf ZJ; Genentech, San Francisco, CA, USA.
van Dam PJ; CellCarta N V, Wilrijk, Belgium.
Rodriguez-Vida A; Hospital del Mar, Barcelona, Spain.
Duran I; Instituto de Biomedicina de Sevilla, IBiS/Hospital Universitario Virgen del Rocio/CSIC/Universidad de Sevilla, Seville, Spain.
Crabb SJ; Southampton Experimental Cancer Medicine Centre, University of Southampton, Southampton, UK.
Van Der Heijden MS; Department of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
Pous AF; Institut Catala d'Oncologia, Hospital Universitari Germans Trias i Pujol, Badalona, Spain.
Gravis G; Institut Paoli-Calmettes, Marseille, France.
Herranz UA; Hospital Clinico Universitario de Santiago, Santiago De Compostela, Spain.
Protheroe A; Churchill Hospital, Oxford, UK.
Ravaud A; Department of Medical Oncology, Hopital Saint-Andre, University of Bordeaux-CHU, Bordeaux, France.
Maillet D; Hospital Lyon SUD, Lyon, France.
Mendez MJ; Reina Sofia University Hospital, Cordoba, Spain.
Suarez C; Vall d'Hebron Institute of Oncology, Vall d'Hebron University Hospital, Universitat Autonoma de Barcelona, Barcelona, Spain.
Linch M; UCLH, London, UK.
Prendergast A; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
Tyson C; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
Stanoeva D; CellCarta N V, Wilrijk, Belgium.
Daelemans S; CellCarta N V, Wilrijk, Belgium; Medical Biochemistry, Faculty of Pharmaceutical, Biomedical and Veterinary Sciences, University of Antwerp, Antwerp, Belgium.
Rombouts M; CellCarta N V, Wilrijk, Belgium.
Mariathasan S; Genentech, San Francisco, CA, USA.
Tea JS; Genentech, San Francisco, CA, USA.
Mousa K; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK.
Sharma S; Natera, Inc., San Carlos, CA, USA.
Aleshin A; Natera, Inc., San Carlos, CA, USA.
Banchereau R; Genentech, San Francisco, CA, USA.
Castellano D; Hospital 12 de Octubre, Madrid, Spain.
Powles T; Barts Experimental Cancer Medicine Centre, Barts Cancer Institute, Queen Mary University of London, London, UK. Electronic address: .
Pokaż więcej
Źródło :
European urology [Eur Urol] 2022 Aug; Vol. 82 (2), pp. 212-222. Date of Electronic Publication: 2022 May 14.
Typ publikacji :
Clinical Trial, Phase II; Journal Article; Multicenter Study
MeSH Terms :
Antibodies, Monoclonal, Humanized*/administration & dosage
Antibodies, Monoclonal, Humanized*/therapeutic use
Circulating Tumor DNA*/analysis
Neoadjuvant Therapy*/methods
Urinary Bladder Neoplasms*/drug therapy
Urinary Bladder Neoplasms*/genetics
Urinary Bladder Neoplasms*/pathology
Urinary Bladder Neoplasms*/surgery
Cisplatin/therapeutic use ; Cystectomy/methods ; Humans ; Muscle Neoplasms/drug therapy ; Muscles/pathology ; Neoplasm Invasiveness ; Neoplasm Recurrence, Local
Czasopismo naukowe
Tytuł :
Re: Longbin Xiong, Jane K. Nguyen, Yulu Peng, et al. What Happens to the Preserved Renal Parenchyma After Clamped Partial Nephrectomy? Eur Urol. 2022;81:492-500. https://doi.org/10.1016/j.eururo.2021.12.036.
Autorzy :
Ren S; Department of Robotic Minimally Invasive Surgery, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China; Department of Organ Transplantation, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.
Zhong S; Department of Organ Transplantation, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.
Fan S; Department of Robotic Minimally Invasive Surgery, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.
Li X; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China; Department of Pathology, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China.
Zhou F; Department of Robotic Minimally Invasive Surgery, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China; Chinese Academy of Sciences Sichuan Translational Medicine Research Hospital, Chengdu, China.
Wang D; Department of Robotic Minimally Invasive Surgery, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, China. Electronic address: wangdong_.
Pokaż więcej
Źródło :
European urology [Eur Urol] 2022 Aug; Vol. 82 (2), pp. e49. Date of Electronic Publication: 2022 May 13.
Typ publikacji :
Letter
MeSH Terms :
Carcinoma, Renal Cell*
Kidney Neoplasms*/surgery
Humans ; Nephrectomy
Opinia redakcyjna
Tytuł :
Reply to Hyung Joon Kim and Khurshid R. Ghani's Letter to the Editor re: Øyvind Ulvik, Mathias Sørstrand Æsøy, Patrick Juliebø-Jones, Peder Gjengstø, Christian Beisland. Thulium Fibre Laser Versus Holmium:YAG for Ureteroscopic Lithotripsy: Outcomes from a Prospective Randomised Clinical Trial. Eur Urol. 2022;82:73-9.
Autorzy :
Ulvik Ø; Department of Urology, Helse Bergen HF, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway. Electronic address: .
Sørstrand Æsøy M; Department of Urology, Helse Bergen HF, Haukeland University Hospital, Bergen, Norway.
Juliebø-Jones P; Department of Urology, Helse Bergen HF, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Gjengstø P; Department of Urology, Helse Bergen HF, Haukeland University Hospital, Bergen, Norway.
Beisland C; Department of Urology, Helse Bergen HF, Haukeland University Hospital, Bergen, Norway; Department of Clinical Medicine, University of Bergen, Bergen, Norway.
Pokaż więcej
Źródło :
European urology [Eur Urol] 2022 Aug; Vol. 82 (2), pp. e41-e42. Date of Electronic Publication: 2022 May 12.
Typ publikacji :
Letter; Randomized Controlled Trial
MeSH Terms :
Lithotripsy*
Lithotripsy, Laser*
Holmium ; Humans ; Lasers ; Prospective Studies ; Thulium ; Ureteroscopy
Raport
Tytuł :
Robot-assisted Radical Prostatectomy with the Novel Hugo Robotic System: Initial Experience and Optimal Surgical Set-up at a Tertiary Referral Robotic Center.
Autorzy :
Bravi CA; Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; ORSI Academy, Ghent, Belgium; Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy. Electronic address: .
Paciotti M; Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; ORSI Academy, Ghent, Belgium; Department of Urology, IRCCS Humanitas Research Hospital, Rozzano, Milan, Italy.
Sarchi L; Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; ORSI Academy, Ghent, Belgium.
Mottaran A; Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; ORSI Academy, Ghent, Belgium; Division of Urology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
Nocera L; Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; ORSI Academy, Ghent, Belgium; Division of Oncology/Unit of Urology, Urological Research Institute, IRCCS Ospedale San Raffaele, Milan, Italy.
Farinha R; ORSI Academy, Ghent, Belgium.
De Backer P; ORSI Academy, Ghent, Belgium.
Vinckier MH; Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; ORSI Academy, Ghent, Belgium.
De Naeyer G; Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; ORSI Academy, Ghent, Belgium.
D'Hondt F; Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; ORSI Academy, Ghent, Belgium.
De Groote R; Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; ORSI Academy, Ghent, Belgium.
Mottrie A; Department of Urology, Onze-Lieve-Vrouwziekenhuis Hospital, Aalst, Belgium; ORSI Academy, Ghent, Belgium.
Pokaż więcej
Źródło :
European urology [Eur Urol] 2022 Aug; Vol. 82 (2), pp. 233-237. Date of Electronic Publication: 2022 May 12.
Typ publikacji :
Case Reports
MeSH Terms :
Robotic Surgical Procedures*/methods
Robotics*
Humans ; Male ; Prostate/surgery ; Prostatectomy/methods ; Referral and Consultation
Raport
Tytuł :
TNM Staging of Prostate Cancer: Challenges in Securing a Globally Applicable Classification.
Autorzy :
Berlin A; Department of Radiation Oncology, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Brierley J; Department of Radiation Oncology, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Cornford P; Liverpool University Hospitals NHS Trust, Liverpool, UK.
Chung P; Department of Radiation Oncology, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada.
Giannopoulos E; Cancer Education Program, Princess Margaret Cancer Centre, University Health Network. Toronto, Canada.
Mason M; Division of Cancer and Genetics, School of Medicine, Cardiff University, Cardiff, UK; Department of Clinical Oncology, Velindre Cancer Centre, Cardiff, UK.
Mottet N; Department of Urology, University Jean Monnet, St. Etienne, France.
Gospodarowicz M; Department of Radiation Oncology, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada; Radiation Medicine Program, Princess Margaret Cancer Centre, University Health Network, Toronto, Canada. Electronic address: .
Pokaż więcej
Źródło :
European urology [Eur Urol] 2022 Aug; Vol. 82 (2), pp. e52-e53. Date of Electronic Publication: 2022 May 11.
Typ publikacji :
Letter
MeSH Terms :
Prostatic Neoplasms*/pathology
Humans ; Lymphatic Metastasis ; Male ; Neoplasm Staging ; Prognosis
Opinia redakcyjna

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies